Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1CNS 1

Conditions

Meningeal Neoplasms 1Lung Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Brain Neoplasms 1

Interventions

Specimen Handling 49pembrolizumab 44Magnetic Resonance Spectroscopy 37Biopsy 35Cyclophosphamide 33fludarabine 28Cetuximab 20Cisplatin 19Carboplatin 19Bevacizumab 16atezolizumab 15Radiation 15venetoclax 14Fluorouracil 14fludarabine phosphate 13Radiotherapy 13Leucovorin 13Nivolumab 12Gemcitabine 12Pemetrexed 11Oxaliplatin 11Cytarabine 11Irinotecan 10130-nm albumin-bound paclitaxel 10Prednisone 9Paclitaxel 9Immunoglobulin G 9Fulvestrant 9durvalumab 8Temozolomide 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × sapanisertib × 30 days × Clear all
NCT04250545 2026-05-26

Testing of the Anti Cancer Drugs CB-839 HCl (Telaglenastat) and MLN0128 (Sapanisertib) in Advanced Stage Non-small Cell Lung Cancer

National Cancer Institute (NCI)

Phase 1 Active not recruiting
22 enrolled 14 charts
CNSThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Meningeal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡